Innate Pharma
IPHA
8 hedge funds and large institutions have $806K invested in Innate Pharma in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 1 closing their positions.
10% more capital invested
Capital invested by funds: $736K → $806K (+$69.9K)
0.1% more ownership
Funds ownership: 0.29% → 0.4% (+0.1%)
11% less funds holding
Funds holding: 9 → 8 (-1)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Optiver Holding
Amsterdam,
Netherlands
|
+$318K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$41.7K |
| 2 |
ETC
Exchange Traded Concepts
Oklahoma City,
Oklahoma
|
-$21.8K |
| 3 |
Millennium Management
New York
|
-$7.26K |
| 4 |
Morgan Stanley
New York
|
-$6.14K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Optiver Holding
Amsterdam,
Netherlands
| $481K | +$318K | +108,423 | +133% |
|
|
2
Millennium Management
New York
| $119K | -$7.26K | -2,477 | -5% |
|
|
3
Morgan Stanley
New York
| $114K | -$6.14K | -2,095 | -4% |
|
|
ETC
4
Exchange Traded Concepts
Oklahoma City,
Oklahoma
| $88.5K | -$21.8K | -7,433 | -18% |
|
|
SPIA
5
Steward Partners Investment Advisory
New York
| $1.26K | – | – | – |
|
6
Barclays
London,
United Kingdom
| $1.04K | – | – | – |
|
7
RhumbLine Advisers
Boston,
Massachusetts
| $518 | – | – | – |
|
8
UBS Group
Zurich,
Switzerland
| $369 | – | – | – |
|
|
9
Citadel Advisors
Miami,
Florida
| – | -$41.7K | -13,281 | Closed |
|
IPHA Hedge Fund Activity: Q3 2023 in Review
8 of the 6,303 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q3 2023, worth a combined $806K — up 9.5% from $736K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of IPHA and 0 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 1 added.
The largest buyer was Optiver Holding, adding an estimated $318K. The largest seller was Citadel Advisors, exiting entirely with an estimated $41.7K sold.
- 8 institutional investors held Innate Pharma (IPHA) as of Q3 2023, down from 9 in Q2 2023.
- Funds reported $806K of Innate Pharma stock for Q3 2023, up 9.5% quarter-over-quarter.
- 0 funds opened new Innate Pharma positions in Q3 2023 and 1 closed out, a net change of -1 holder.
- The largest Innate Pharma buyer in Q3 2023 was Optiver Holding, an estimated $318K added.
- The largest Innate Pharma seller in Q3 2023 was Citadel Advisors, an estimated $41.7K sold.
Based on aggregated 13F filings for Q3 2023.